![]() |
|
|
Vol. 286, Issue 1, 439-446, July 1998
Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan
| |
Abstract |
|---|
|
|
|---|
We examined the protective effects of GM2941, a sulfated glycomimetic of the complex carbohydrate sialyl Lewisx, in a model of pulmonary granuloma development. This study was based on the rationale that formation of glucan-induced lung granulomas is dependent on neutrophils and that sialyl Lewisx glycomimetic (GM2941) interferes, in vitro, with P-selectin-dependent neutrophil-endothelial adhesive interactions. Infusion of particulate yeast cell wall glucan into rats results in the rapid (48 hr) formation of monocyte/macrophage-rich angiocentric pulmonary granulomas. Development of granulomas exhibits a temporal pattern characterized by the early, transient influx of neutrophils into blood vessel walls at sites of glucan embolization, followed by accumulation of monocytes and macrophages that constitute the definitive angiocentric lesions. Within 1 hr after the infusion of glucan, immunohistochemical analysis revealed up-regulation of blood vessel wall-associated P-selectin. Previous studies utilizing neutrophil-depleted animals have revealed that neutrophils, although not present in definitive lesions, are required for full granuloma development. The potential of GM2941 to inhibit neutrophil-endothelial cell adhesive interactions was demonstrated by the ability of the compound to inhibit P-selectin-mediated adhesion to histamine-stimulated HUVECs. Infusion of GM2941 retarded pulmonary granuloma development in a dose-dependent manner. Whole-lung myeloperoxidase activity, measured at the time of peak neutrophil accumulation, was significantly reduced in animals pretreated with GM2941 (30 mg/kg, 24 µM/kg), which suggests that this compound affords protection, at least in part, through impedance of neutrophil recruitment. These data indicate that GM2941 affords a significant degree of protection against granuloma formation associated with glucan infusion, probably through the interruption of neutrophil recruitment.
| |
Introduction |
|---|
|
|
|---|
A
large body of data indicates that neutrophils play a central role in
the pathogenesis of diverse pulmonary diseases, including the ARDS,
emphysema and a variety of acute vasculitic diseases (Gadek, 1992
;
Mulligan et al., 1992a
; Henderson et al., 1991
). The recruitment of neutrophils into sites of acute inflammation is
mediated through the expression of a series of intercellular adhesion
molecules expressed on both neutrophils and endothelial cells
(reviewed, Pardi et al., 1992
; Zimmerman et al.,
1992
). The initial events in neutrophil adhesion encompass an early
(less than 1 hr), relatively weak tethering or rolling interaction that is mediated by members of the selectin family. These include
P-selectin, which is expressed on endothelial cells, and L-selectin,
which is expressed on neutrophils (Lasky, 1992
). Upon activation of endothelial cells by an agonist such as thrombin or histamine (Zimmerman et al., 1992
; Lorant et al., 1991
) or
by complement-derived factors including C5a and the membrane attack
complex (Foreman et al., 1994
; Hattori et al.,
1989
), P-selectin is rapidly translocated from Weibel-Palade bodies to
the cell surface where it can interact with its counterligand on the
neutrophil (Varki, 1992
; Moore et al., 1992
). This
counterligand is believed to be a sialylated O-linked
oligosaccharide-containing glycoprotein (e.g.,
sLex) or other related sulfated glycoproteins and
glycolipids (Moore et al., 1992
; Norgard et al.,
1993
). Once weakly bound to the endothelium, the neutrophil can
establish a firm, irreversible adhesive interaction mediated by members
of the
2 integrin and intercellular adhesion molecule
families (Lawrence and Springer, 1991
; von Andrian et al.,
1991
). A large body of in vitro and in vivo data
indicates that both selectin- and
2 integrin-dependent leukocyte-endothelial adhesive interactions are required for emigration of leukocytes from the vascular space (Lawrence and Springer, 1991
; von
Andrian et al., 1991
).
The i.v. infusion of particulate yeast cell wall glucan into rats
results in the rapid, synchronous development of foreign body-type lung
granulomas composed almost entirely of monocytes and macrophages (Flory
et al., 1993
; Jones and Warren, 1992
). A number of systemic
diseases, including Wegener's granulomatosis, sarcoidosis and several
occupational lung diseases (e.g., berylliosis and talcosis),
are characterized by the presence of monocyte-rich granulomas that
resemble those found in rats after glucan infusion (Shellito et
al., 1987
; Lugano et al., 1982
; van Oud Albas et al., 1983a
; Kilgore et al., 1997
). Glucan-induced
granuloma formation exhibits a characteristic temporal pattern that
involves the local synthesis of chemotactic cytokines and the
recruitment of leukocytes into sites of glucan deposition (Flory
et al., 1993
; Jones and Warren, 1992
; Flory et
al., 1994
). We have previously observed that MCP-1 is required for
full granuloma development (Flory et al., 1993
; Flory
et al., 1994
). Early (within 1 hr) in the evolution of
granuloma formation, there is a rise in MCP-1 expression that is
associated with blood vessel wall cells. Later (24 hr), there is a
second rise in MCP-1 expression that is associated with granuloma cells
per se. The early rise in MCP-1 activity is temporally and anatomically associated with the transient influx of neutrophils into
vessel walls (at sites of glucan embolization)
hence the hypothesized
relationship between locally elaborated neutrophil products and
granuloma formation. The transient, early influx of neutrophils into
blood vessel walls at sites of glucan embolization suggests that
neutrophils may play a role in formation of these lesions, despite the
fact that mature granulomas do not contain neutrophils.
Recent studies from our laboratory have focused on the role of the
neutrophil in the pathogenesis of granuloma formation. Depletion of
circulating neutrophils through the use of a selective antibody
directed against rat neutrophils results in a significant decrease in
granuloma size and number, which suggests a relationship between
neutrophil influx and subsequent granuloma development (Kilgore
et al., 1997
). This hypothesis is supported by the
observations that neutrophil depletion is associated with decreased
expression of MCP-1 at both the mRNA and protein levels and that both
activated neutrophils and H2O2 can induce MCP-1
production by isolated endothelial cells (Kilgore et al.,
1997
). The temporal and anatomic linkage between localized neutrophil
influx and the subsequent expression of chemotactic cytokines, in
conjunction with a growing literature indicating that ROIs can induce
chemokine expression (Satriano et al., 1993
; DeForge
et al., 1993
), suggests that neutrophils may play an
important role in mediating this inflammatory process.
Inhibition of neutrophil-endothelial adhesion by interrupting
P-selectin-dependent neutrophil-endothelial cell interactions has
retarded the development of tissue injury in a number of pathologic conditions, including complement-mediated lung injury and myocardial reperfusion injury (Mulligan et al., 1992a
; Kilgore et
al., 1995
; Weyrich et al., 1993
). The purpose of the
present study was to assess the potential of carbohydrate-based
therapeutics (Musser et al., 1995a
; Oppenheimer-Marks and
Lipsky, 1996
; Musser et al., 1996
; Rao et al.,
1994
), specifically a novel glycomimetic of sLex (Rao
et al., 1994
), to prevent the development of glucan-induced pulmonary granulomas in the rat. In this study, GM2941 (fig.
1), a sulfated form (Musser et
al., 1995b
) of a previously reported glycomimetic (Anderson
et al., submitted for publication), was examined. The
results of this study indicate that GM2941 significantly retards
granuloma development in a dose-dependent manner. The observation that
GM2941 infusion reduces whole-lung MPO activity, coupled with
morphologic studies revealing decreased numbers of blood vessel wall
neutrophils at sites of glucan embolization, suggests that interruption
of neutrophil recruitment is an important mechanism of action for this
compound.
|
| |
Materials and Methods |
|---|
|
|
|---|
Preparation of GM2941. GM2941 was a gift from Glycomed Incorporated (Alameda, CA). The compound is soluble when dissolved in sterile saline (pH 7.4). GM2941 was prepared immediately before use in a stock solution from which aliquots were taken and added to the glucan solution to achieve the desired dose. The final volume administered was 1.1 ml, which was infused over 1 min.
Endothelial cell culture.
HUVECs were isolated from
umbilical veins by treatment with 0.1% collagenase in Dulbecco's
modified Eagle's medium (Jaffee, 1984
). Cells were plated in
gelatin-coated 48-well plates and incubated at 37°C, 5%
CO2. Cells were grown in M199 medium supplemented with 20%
heat-inactivated fetal calf serum, L-glutamine (4 mM), penicillin (100 U/ml), streptomycin (100 µg/ml), 25 µg/ml
endothelial cell growth supplement (Collaborative Research, Bedford,
MA) and 15 U/ml bovine heparin. Cells were characterized by a
cobblestone appearance and utilized between the first and third
passages.
Isolation and fluorescence labeling of human neutrophils.
Human neutrophils were isolated by Ficoll/Hypaque (Pharmacia, Uppsala,
Sweden) centrifugation and dextran (MW 200,000; Sigma Chemical Co.)
sedimentation as described previously (Foreman et al.,
1994
). Contaminating erythrocytes were removed by hypotonic lysis.
Cells preparations were
90% pure with a viability of approximately 95% as determined by trypan blue exclusion. Neutrophils were
fluorochrome-labeled as described previously, using BCECF-AM (Molecular
Probes, Eugene, OR) (Vaporciyan et al., 1993
). Briefly,
BCECF-AM was dissolved in dimethyl sulfoxide to achieve a final
concentration of 1 µg/µl. One microliter of BCECF-AM was added per
1.0 ml of cells (final concentration of 1 µM) and incubated for 30 min at 37°C. The cells were washed two times in
HBSS
/BSA and resuspended in serum free HUVEC medium to
achieve a final concentration of 1 × 106 cells/ml.
Neutrophil endothelial cell adhesion assay.
The ability of
GM2941 to decrease P-selectin-mediated neutrophil adherence to HUVEC
monolayers was quantitated as previously described (Vaporciyan et
al., 1993
). To promote P-selectin expression, monolayers were
treated for 10 min with 10 mM histamine and washed three times with
warm serum-free HUVEC media, followed by the addition of
BCECF-AM-labeled neutrophils (1.0 × 105 cells/well,
100 µl total volume). After a 15-min incubation, nonadherent
neutrophils were removed by washing with PBS. The amount of
fluorescence was determined with a Cytofluor 2300 fluorescent plate
reader (Millipore) using a 20-nm bandwidth filter centered at 485 nm
and a 25-nm emission bandwidth filter centered at 530 nm. Where
indicated, GM2941 (3 mg/ml) was added to endothelial monolayers 5 min
before the addition of BCECF-AM-labeled neutrophils. The
anti-P-selectin antibody Throm/6 (Biodesign Int., Kennebunkport, ME; 10 µg/ml) was utilized as a positive control.
Glucan-induced pulmonary granulomatosis.
Male, pathogen-free
Long Evans rats (250-300 g, Charles River, Portage, MI) were housed in
specific pathogen-free rooms with laminar air flow. Veterinary care was
provided by the University of Michigan Unit for Laboratory Animal
Medicine. Pulmonary granulomas were induced by infusion of particulate
glucan (5 mg/rat; Sigma Chemical Company, St. Louis, MO) into
anesthetized (ketamine; 3.0 mg/100 g b.wt.) animals as described
previously (Flory et al., 1993
). For in vivo
interventions with GM2941, glucan and the indicated dose of GM2941 were
infused via the dorsal penile vein. Control rats were
treated identically except that an equivalent volume of vehicle
(saline) was substituted for GM2941.
Immunohistochemical analysis of P-selectin expression.
The
anatomic distribution of P-selectin and MCP-1 expression was examined
by immunohistochemistry as previously described (Mulligan et
al., 1992b
; Flory et al., 1993
). The murine monoclonal antibody to human P-selectin, PB1.3 (Cytel Corporation, San Diego, CA),
was utilized for P-selectin immunohistochemistry and has previously
been shown to recognize rat P-selectin (Mulligan et al.,
1992a
). Controls included sections treated with a nonimmune primary
antibody and sections in the absence of primary antibody. Detection of
the primary antibodies was accomplished using a Vectastain ABC kit
(Vector Laboratories, Burlingame, CA). The peroxidase substrate was
3-amino-9-ethyl-carbazole.
Lung MPO assay: quantitation of neutrophil accumulation.
A
whole-lung MPO assay was used to quantitate pulmonary neutrophil
recruitment (Mulligan et al., 1992b
). Lungs harvested for MPO analysis were immediately frozen in liquid N2. At the
time of MPO assay, tissue was placed in 2 volumes of homogenization buffer (50 mM sodium phosphate, pH 6.0) and homogenized (4 × 10 sec at setting 5) with a Polytron homogenizer (Tekmar Co., Cincinnati, OH). The homogenates were centrifuged for 30 min (3000 × g, 4°C) and the supernatants removed. Myeloperoxidase
activity was determined by measuring the change in absorbance at 460 nm
resulting from the conversion of H2O2 in the
presence of o-dianisidine (Sigma) as previously described
(Mulligan et al., 1992b
). MPO activity measurements were
normalized to the wet weight of the tissue.
Effect of GM2941 on expression of P-selectin.
The ability of
GM2941 to inhibit histamine-mediated P-selectin expression was
determined by a modified whole-cell ELISA assay as described previously
(Foreman et al., 1994
). Monolayers were treated with 10 mM
histamine for 10 min in the presence or absence of GM2941 (3 mg/ml).
Cells were washed with PBS and fixed with 1% paraformaldehyde for 30 min, followed by the addition of nonfat dry milk (5% in PBS). Cells
were incubated with the anti-P-selectin monoclonal antibody PB1.3 (1 µg/ml) or with an isotype-matched murine antibody for 45 min,
followed by incubation with the peroxidase-conjugated goat anti-mouse
secondary antibody (Dako Corporation, Carpinteria, CA) for 45 min.
Cells were washed with PBS and then exposed to the substrate
(o-phenylenediamine dihydrochloride, Sigma) for 30 min. The
reaction was halted by addition of 3 M sulfuric acid. Optical density
was determined by an automated microplate reader (EL340, Bio-Tek
Instruments, Winooski, VT) set to a wavelength of 495 nm.
Statistical data.
The data presented in the text, figures
and tables are expressed as mean ± S.E.M. for the indicated
number of determinations. A one-way ANOVA (repeated-measures) was used
to assess differences over time within groups. One-way analysis of
variance (factorial) was used for group comparisons. If significance
was determined, Sheffé's test was used as a post-hoc
analysis. Student's t test was used to examine statistical
differences between treatment groups (Linton and Gallow, 1975
). A P
value less than .05 was considered significant. All statistical
evaluations were performed using a Macintosh 8500 computer (Apple
Computer, Cupertino, CA) with Statview software (Abacus Concepts Inc.,
Berkeley, CA).
| |
Results |
|---|
|
|
|---|
GM2941 decreases P-selectin-mediated neutrophil adhesion to histamine-stimulated HUVEC monolayers. To determine the potential of GM2941 to inhibit P-selectin-mediated neutrophil-HUVEC adhesive interactions, we stimulated HUVEC monolayers with histamine (10 mM) for 10 min. After incubation of HUVECs with histamine, GM2941 (3 mg/ml; 2.4 µM) was added to monolayers for 5 min, followed by the addition of BCECF-labeled human neutrophils. Neutrophils were allowed to incubate with the HUVECs at 37°C for 15 min. Incubation with GM2941 decreased neutrophil adhesion by 86% compared with monolayers treated with vehicle alone (fig. 2; P < .05, one-way ANOVA). Use of the anti-P-selectin antibody Throm/6 (10 µg/ml) resulted in a similar degree of inhibition. Use of a nonspecific isotype-matched antibody did not decrease the degree of neutrophil adhesion (results not shown). These data demonstrate that GM2941 has the ability to decrease P-selectin-mediated neutrophil adhesion in vitro.
|
Pulmonary vascular expression of P-selectin after glucan infusion. Immunohistochemical analysis using the anti-P-selectin murine monoclonal antibody PB1.3 was carried out in order to examine the temporal and anatomic distributions of P-selectin expression after glucan infusion. As shown in figure 3A, positive staining for P-selectin was evident in the vascular walls of rats by 30 min after glucan infusion. In contrast, little immunoreactivity was present in sections removed immediately after glucan infusion (time zero; fig. 3B). Sections of tissue removed 30 min after the infusion of glucan but incubated with nonspecific IgG revealed no staining for P-selectin (results not shown). These results indicate that infusion of glucan is associated with a rapid (30-min) increase in P-selectin expression in the walls of pulmonary blood vessels.
|
Effect of GM2941 on circulating WBC concentrations. In order to determine the effect of GM2941 on circulating cell WBC concentrations, we conducted WBC and differential counts on whole-blood samples obtained 48 hr after GM2941 (30 mg/kg) administration (table 1). The concentrations of circulating neutrophils, monocytes and lymphocytes were not significantly different in animals treated with GM2941 compared with vehicle-treated animals. In addition, the concentration of circulating red blood cells was not affected by the compound (results not shown). Thus, infusion of GM2941 into rats is not associated with alterations in the concentrations of circulating blood cells.
|
GM2941 infusion inhibits glucan-induced pulmonary granuloma formation. GM2941 (30 mg/kg, 24 µM) resulted in reduced glucan-induced formation (table 2). An 80% reduction in average granuloma profile area was observed after 48 hr in GM2941-treated rats as compared with the vehicle control group (mean granuloma sizes 2734 ± 353 µm2 and 13,728 ± 1104 µm2, respectively (P < .05). Preliminary studies revealed that similar degrees of inhibition against granuloma formation were achieved in rats that received a single infusion of GM2941 as compared with those that also received a booster injection 24 hr after glucan infusion (results not shown).
|
|
|
GM2941 infusion prevents glucan-induced pulmonary neutrophil
accumulation after glucan infusion.
Quantitative measurements of
whole-lung MPO activity, a quantitative measurement of neutrophil
accumulation (Bradley et al., 1982
), were obtained from
GM2941-treated and vehicle-treated control animals to determine the
effect of GM2941 on neutrophil recruitment (fig.
6). Rat lungs were removed 6 hr after
infusion of glucan. Lungs from GM2941-treated animals (30 mg/kg)
exhibited a significant decrease in MPO activity when compared with the
lungs of vehicle-treated animals. These data suggest that GM2941
infusion significantly reduces pulmonary neutrophil accumulation
measured at 6 hr.
|
GM2941 does not directly influence P-selectin expression. A whole-cell ELISA assay was performed to examine potential direct effects of GM2941 on P-selectin expression by HUVECs. Endothelial cell monolayers were treated with histamine (10 mM) for 10 min in the absence or presence of GM2941 (3 mg/ml), and P-selectin expression was quantified. As shown in figure 7, histamine significantly increased P-selectin expression as compared with control. Incubation of HUVEC monolayers with histamine in the presence of GM2941 was also associated with a significant increase in P-selectin. There was no difference in P-selectin expression between monolayers treated with histamine plus GM2941 and those treated in the absence of the glycomimetic compound. These results indicate that GM2941 does not directly affect the degree of expression of P-selectin.
|
| |
Discussion |
|---|
|
|
|---|
Neutrophils are important in the pathogenesis of a wide variety of
human lung diseases, including emphysema, ARDS and disease states
incurred through the inhalation of particles (e.g., silica, quartz) (Henderson et al., 1991
; Lugano et al.,
1982
; Bowden and Adamson, 1978
). Neutrophils have recently been shown
to play an essential role in pulmonary granuloma development after the
i.v. infusion of yeast cell wall glucan into rats (Kilgore et
al., 1997
). The requirement for neutrophils in granuloma
development suggests that the glucan-induced granulomatous vasculitis
model may be both useful and relevant in the assessment of
pharmacologic interventions that limit the degree of neutrophil
accumulation at sites of acute inflammation. In the present study, we
examined the potential of the carbohydrate-based sLex
glycomimetic GM2941 to prevent the development of glucan-induced pulmonary granulomas in the rat.
As revealed in the present study, the expression of the adhesion
molecule P-selectin is increased after glucan infusion. Furthermore, ICAM-1 has previously been shown to be up-regulated (Kishimoto et
al., 1994
). Direct evidence implicating neutrophils in
glucan-induced granuloma formation has been obtained from studies that
employed rats depleted of circulating neutrophils through the use of an antineutrophil antibody (Kilgore et al., 1997
). Neutrophil
depletion results in a significant reduction in granuloma size and
number. A similar reduction in granuloma size was noted when animals
were pretreated with the ROI scavenger catalase, a result that suggests a role for H2O2 in granuloma development. Both
neutrophil depletion and pretreatment with catalase cause a marked
decrease in pulmonary MCP-1 mRNA and protein expression (Kilgore
et al., 1997
). These data, in conjunction with in
vitro data indicating that H2O2 and activated neutrophils can directly induce MCP-1 secretion, suggest that
neutrophils (or their secreted products, such as
H2O2) play a role in granuloma formation
through the induction of proinflammatory mediators (e.g.,
MCP-1). Accordingly, pharmacologic approaches designed to disrupt
adhesive interactions between circulating neutrophils and pulmonary
endothelial cells may be useful in retarding pulmonary granuloma
formation.
The sLex sulfated glycomimetic GM2941 significantly reduced
both granuloma size and number measured 48 hr after glucan infusion. These protective effects were associated with a marked decrease in
early (6 hr) neutrophil accumulation within the lungs of treated rats.
The primary mechanism by which GM2941 reduces granuloma size and number
has yet to be fully elucidated, but both in vitro and
in vivo data from this study suggest that this compound
interrupts P-selectin-mediated neutrophil-endothelial adhesive
interactions. Several investigators have proposed a two-step model of
neutrophil-endothelial adhesion whereby L- and P-selectin act in
concert to facilitate the recruitment of neutrophils into the
microenvironment of the vasculature (von Andrian et al.,
1991
; Lorant et al., 1991
). The initial adhesive interaction
between neutrophils and endothelium is mediated by endothelium-derived
P-selectin and its carbohydrate ligand sLex, which is
located on the surface of neutrophils. Another member of the selectin
family, L-selectin, which is found on the neutrophil surface, is also
involved in tethering the neutrophil to the endothelial cell surface
(Lasky, 1992
). The relatively weak "rolling" adhesive interaction
that occurs between neutrophils and the endothelial surface is a
prerequisite for a more firm adhesion mediated by the interaction of
the
2 integrins (e.g., CD11b/CD18) with
the their endothelial counterligands (ICAM-1) (Lawrence and
Springer, 1991
).
The observation that neutrophil adhesion and subsequent migration from
the vasculature is a multistep process suggested that disruption of one
or more of these processes may serve to prevent or reduce
neutrophil-mediated tissue injury. Immunohistochemical analysis of lung
tissue from glucan-treated animals confirmed the rapid (within 30 min)
expression of P-selectin by the vascular endothelium. We confirmed
in vitro that GM2941 inhibits P-selectin-mediated neutrophil
adhesion to histamine-activated endothelial cells and that GM2941 does
not directly affect MCP-1 secretion. The ability of GM2941 to inhibit
neutrophil adhesion in vitro suggests that this may be a
mechanism by which the compound prevents granuloma formation in
vivo. Whole-lung MPO activity, which has previously been shown to
be a quantitative measure of net neutrophil accumulation (Bradley
et al., 1982
), was measured to assess the extent of
neutrophil infiltration in the lungs of animals treated with vehicle or
GM2941. Infusion of GM2941 was associated with decreased pulmonary
neutrophil accumulation as compared with neutrophil accumulation in the
lungs of vehicle-treated animals. The relatively modest reduction in neutrophil accumulation (24%) suggests that inhibition of
P-selectin-sLex-mediated neutrophil-endothelial adhesive
interactions may not be the sole mechanism of action by which GM2941
affords protection against granuloma development. In fact, on the basis
of a large body of data, redundancy among the mechanisms of neutrophil
recruitment would be expected (Kishimoto et al., 1994
;
Strieter et al., 1993
; Stoolman, 1993
).
In this and previous studies (Flory et al., 1993
; Jones and
Warren, 1992
), we have utilized two-dimensional morphometric methods for quantitation of granuloma size and number. It should be noted, however, that there are limitations to this approach. Larger granulomas will appear with greater frequency and therefore have a greater probability than smaller granulomas of appearing in a given histologic section. Three-dimensional methods are available and offer a greater degree of sensitivity (Sterio, 1984
; Ogbuihi and Cruz-Orive, 1990
), but
the large differences in granuloma size observed in the present study
indicate that the diminished sensitivity of two-dimensional analysis is
unlikely to affect interpretation of the results of this study.
It has been suggested that firm attachment of the neutrophils to
endothelium is required for the subsequent migration of the neutrophil
out of the vasculature (Nathan, 1987
). Therefore, GM2941, by preventing
firm attachment of neutrophils to the vascular endothelium, may
ultimately decrease the number of cells available for transendothelial migration. One may speculate that GM2941 not only inhibits the early
events of adhesion (rolling of the neutrophil along the endothelium),
mediated by P- and L-selectin, but also inhibits later stages (firm
adhesion to the endothelium), mediated in part by E-selectin. An
alternative mechanism by which GM2941 may prevent granuloma formation
is through yet-undetermined intracellular or extracellular effects that
result in inhibition of the release of neutrophil-derived products
(e.g., ROIs, cytotoxic proteases). Nathan (1987)
has
demonstrated that firm adhesion is required for maximal release of
oxidants from neutrophils stimulated by soluble inflammatory mediators.
GM2941, by impairing the early events associated with adhesion, may act
to prevent or reduce the release of neutrophil-derived mediators. It is
also possible that GM2941 acts on endothelial cells to inhibit the
expression of P-selectin directly, though this is unlikely, given that
GM2941 did not alter the histamine-mediated induction of P-selectin by HUVECs as determined by a whole-cell ELISA. It is clear, however, that
the mechanism of protection noted in this study cannot be attributed to
a general leukopenia, as evidenced by the similar numbers of
circulating neutrophils in treated and control animals.
Prevention of neutrophil adhesion through the use of GM2941 may provide
both direct and indirect protection against pulmonary granuloma
formation after glucan infusion. The direct action of the compound, as
we have noted, probably occurs through the inhibition of neutrophil
adhesion/function and a resulting reduction in the extent of cellular
damage mediated by the secretion of neutrophil-derived products
(e.g., ROI, proteolytic enzymes). GM2941 and similar agents
may also act indirectly to protect against granuloma formation by
reducing the expression of proinflammatory mediators. Monocyte chemoattractant protein-1 is a monocyte-specific chemokine that has
previously been shown to be required for full granuloma formation (Flory et al., 1993
; Jones and Warren, 1992
). Within 1 hr
after glucan infusion, there is an increase in MCP-1 expression
localized primarily to blood vessel wall cells. A second peak of MCP-1
expression is seen 24 hr after glucan infusion and is associated with
lesional cells per se. The early rise in MCP-1 activity is
associated with the transient influx of neutrophils into vessel walls
and perivascular space (Flory et al., 1994
). The temporal
relationship between neutrophils and MCP-1 expression suggests that
neutrophils may play a role in mediating the induction and expression
of MCP-1 by resident alveolar cells. Previous in vitro
studies using LPS-stimulated HUVECs have demonstrated that GM2941 does
not directly alter the up-regulation of MCP-1 production (unpublished
observation), which suggests that the compound is not exerting its
protective effects by directly decreasing MCP-1 secretion. Thus,
modulating neutrophil function with GM2941 may have an important
influence on the up-regulation of MCP-1 and/or other proinflammatory
cytokines. The importance of neutrophils in mediating monocyte
recruitment is further exemplified by Doherty et al. (1988)
,
who demonstrated, using a rabbit model of C5 fragment-induced lung
inflammation, that the recruitment and migration of monocytes are
neutrophil-dependent. That neutrophils are required for subsequent
monocyte recruitment/migration, as demonstrated by previous studies
(Kilgore et al., 1997
; Doherty et al., 1988
),
underscores the potential value of inhibiting neutrophil adhesion in
the setting of pulmonary inflammation.
The results of this investigation demonstrate that the sulfated sLex glycomimetic GM2941 has a salutary effect in reducing the degree of granuloma formation after the i.v. infusion of glucan. Moreover, the results derived from this study agree with the concept that the early, selectin-mediated adhesion of neutrophils at sites of glucan embolization is an important prerequisite for full granuloma formation. Thus these observations not only provide an understanding of the potential pharmacologic applications for GM2941 and similar agents but also offer further insight into the pathologic basis for pulmonary granuloma formation.
| |
Acknowledgments |
|---|
The authors wish to thank Drs. John H. Musser and Stu Swiedler for the helpful discussions and Haresh Vazin for assistance.
| |
Footnotes |
|---|
Accepted for publication March 2, 1998.
Received for publication August 15, 1997.
1 These studies were supported in part by the National Institutes of Health (HL 48287 and 5T 32-HL 07517).
2 K.S.K. was supported in part by the American Heart Association of Michigan (21F956 Fellowship).
3 M.B.A. is a senior research scientist in Medicinal Chemistry at Glycomed Incorporated (a fully owned subsidiary of Ligand Pharmaceuticals Incorporated) of Alameda, CA.
Send reprint requests to: Jeffrey S. Warren, M.D., Department of Pathology, Box 0602, University of Michigan Medical School, 1301 Catherine Road, Ann Arbor, MI 48109-0602.
| |
Abbreviations |
|---|
sLex, sialyl Lewisx; ARDS, adult respiratory distress syndrome; MCP-1, monocyte chemoattractant protein-1; ROIs, reactive oxygen intermediates; MPO, myeloperoxidase; HUVECs, human umbilical vein endothelial cells; BCECF-AM, 2',7'-bis-(2-carboxyethyl)-5(and 6)-carboxyfluorescein, acetoxymethyl; WBC, white blood cell; ELISA, enzyme-linked immunoabsorbant assay; PBS, phosphate-buffered saline; HBSS, Hanks' balanced salt solution; BSA, bovine serum albumin.
| |
References |
|---|
|
|
|---|
and interleukin-1
in monocyte chemoattractant protein-1 mediated pulmonary granuloma formation in the rat.
Am J Path
146:
450-462[Abstract].
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||